allogeneic

Type: Keyphrase
Name: allogeneic
First reported 7 hours ago - Updated 7 hours ago - 1 reports

Langerhans Cell Homeostasis and Turnover After Nonmyeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation

BackgroundLangerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime ... [Published Transplantation - 7 hours ago]
First reported 13 hours ago - Updated 12 hours ago - 1 reports

Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology

Regulatory News:Cellectis (Alternext: ALCLS.PA), a leader in the development of adoptiveimmunotherapies based on engineered allogeneic CART cells (UCART) willhost a R&D/ Analyst Day on Thursday, September 11 at 7:30AM in New YorkCity. Cellectis’ scientists ... [Published Ask.com - 13 hours ago]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Issue Summary September 2, 2014

issue, including articles on low-carbohydrate and low-fat diets, HIV-1 remission and viral rebound after allogeneic hematopoietic stem cell transplantation, diabetes prevalence in the United States, fluid resuscitation in sepsis, as well as the USPSTF ... [Published Annals of Internal Medicine - Sep 02 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Advances in Hematopoietic Cell Transplant for Pediatric AML Reduce Toxicity and Expand Access, but Relapse Remains a Problem

Figures:John Perentesis, MDJohn Horan, MDOne of the real successes in using hematopoietic cell transplantation for children with AML has been in developing better conditioning regimens and the reduction in regimen-related toxicity.—John Horan, MDAdvances ... [Published The ASCO Post - Sep 02 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Emerging Approaches in Acute Myeloid Leukemia

Figures:Hugo F. Fernandez, MDThe future of AML sees us aggressively treating this disease in induction and consolidation. Molecular targets are being discovered, and directed therapy will hopefully improve upon remission rates and overall survival in ... [Published The ASCO Post - Sep 02 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, ...

We have previously shown that lymphopenia and monocytopenia at 2-3 months post-allogeneic haematopoietic cell transplant (HCT) is associated with poor survival in recipients of both myeloablative and reduced intensity conditioning regimens. It is not ... [Published 7thSpace - Sep 01 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Angiopoietin-Like Protein 3 Promotes Preservation of Stemness during Ex Vivo Expansion of Murine Hematopoietic Stem Cells

by Elnaz Farahbakhshian, Monique M. Verstegen, Trudi P. Visser, Sima Kheradmandkia, Dirk Geerts, Shazia Arshad, Noveen Riaz, Frank Grosveld, Niek P. van Til, Jules P. P. MeijerinkAllogeneic hematopoietic stem cell (HSC) transplantations from umbilical ... [Published Plosone.org - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Interest in Using Stem Cells in Spinal Surgery Increasing

Data and regulations are drivers of researchFrank B. Kelly, MD, and Mary Ann Porucznik“The world of spinal biologics is very exciting, not only because the spine has so many different tissues to regenerate, but also because the conditions that affect ... [Published News and Journals - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

BloodCenter of Wisconsin Launches Erythroid Chimerism Test for Monitoring Transplanted Sickle Cell Disease Patients

MILWAUKEE, Aug. 28, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of an innovative Erythroid Chimerism test to monitor erythroid lineage chimerism in patients with sickle cell disease ... [Published PR Newswire: Policy & Public Interest - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Shift of HIV Tropism in Stem-Cell Transplantation with CCR5 Delta32 Mutation

To the Editor:Infection with the human immunodeficiency virus (HIV) requires entry into target cells by binding of the viral envelope to the CD4 receptor and to either the chemokine (C-C motif) receptor 5 (CCR5) or the chemokine (C-X-C motif) receptor ... [Published New England Journal of Medicine - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

TiGenix Business and Financial Update for the First Half of 2014

Company:TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory ... [Published Angel News - Aug 28 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

Findings from Shinshu University Hospital Provides New Data about Stem Cells (Safety, tolerability, and feasibility of antifungal prophylaxis with...

Findings from Shinshu University Hospital Provides New Data about Stem Cells (Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell ...)By a ... [Published 4 Traders - Aug 28 2014]

Quotes

...advancing PRM-151 to better meet the needs of patients with myelofibrosis," said Suzanne Bruhn, president and chief executive officer of Promedior. "Based on the encouraging clinical results reported to date in myelofibrosis patients we believe that PRM-151’s novel mechanism of action is compelling with its potential to target and reverse the fundamental bone marrow fibrosis that underlies patients’ disease."
...this is a very important clue, that an immune response produced by bone marrow transplantation has such a strong anti-HIV effect," Cooper added. "We're going to use this as a model for cure research and see if we can develop some therapies that mimic what were doing with bone marrow transplantation."
...individuals who are committed to moving ValloVax™ closer to becoming a promising option for those suffering from lung cancer," Wagner said. "This motivation, combined with the rapid advancement of technology to evaluate a patient's immune response, will allow Batu Biologics to swiftly move to the forefront of innovative cancer treatments that improve patients' quality of life." About Batu Biologics: Batu Biologics is a biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area...

More Content

All (282) | News (208) | Reports (0) | Blogs (65) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
The changing global distribution and prevalence... [Published BMC - 2 hours ago]
The changing global distribution and prevalence... [Published 7thSpace - 2 hours ago]
Handbook of Diabetes, 4th Edition, Excerpt #9: ... [Published Diabetes in Control - 6 hours ago]
Who Is the Best Hematopoietic Stem-Cell Donor f... [Published Transplantation - 7 hours ago]
Langerhans Cell Homeostasis and Turnover After ... [Published Transplantation - 7 hours ago]
FDA Names Myelofibrosis Treatment an Orphan Drug [Published Drug Discovery and Development - 7 hours ago]
Cellectis: Genome Engineering & CART Cells: At ... [Published Ask.com - 13 hours ago]
Promedior Receives U.S. Orphan Drug Designation... [Published Market Pulse Navigator - 17 hours ago]
Issue Summary September 2, 2014 [Published Annals of Internal Medicine - Sep 02 2014]
Advances in Hematopoietic Cell Transplant for P... [Published The ASCO Post - Sep 02 2014]
Emerging Approaches in Acute Myeloid Leukemia [Published The ASCO Post - Sep 02 2014]
Impact of clinical factors and allograft leukoc... [Published 7thSpace - Sep 01 2014]
Managing Infections in Pregnancy [Published General Medicine eJournal - Sep 01 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published MarketResearch.com - Aug 30 2014]
MESOBLAST : Company Secretary Appointment/Resig... [Published 4 Traders - Aug 30 2014]
Angiopoietin-Like Protein 3 Promotes Preservati... [Published Plosone.org - Aug 29 2014]
Perioperative blood loss, transfusion need not ... [Published Orthopedics Today - Aug 29 2014]
Chimeric Antigen Receptor (CAR) T-Cell Immunoth... [Published OncLive - Aug 29 2014]
GVHD Industry (Life sciences) Insights & Analys... [Published MyNewsDesk - Aug 29 2014]
Interest in Using Stem Cells in Spinal Surgery ... [Published News and Journals - Aug 28 2014]
AIDS 2014: Australian Bone Marrow Transplant Pa... [Published HIV and Hepatitis.com - Aug 28 2014]
BloodCenter of Wisconsin Launches Erythroid Chi... [Published PR Newswire: Policy & Public Interest - Aug 28 2014]
BioTime to Collaborate With the University of W... [Published The CW44 Tampa Bay - Aug 28 2014]
TiGenix Business and Financial Update for the F... [Published Angel News - Aug 28 2014]
Shift of HIV Tropism in Stem-Cell Transplantati... [Published New England Journal of Medicine - Aug 28 2014]
Batu Biologics Achieves Goal in Successful Crow... [Published HispanicBusiness.com - Aug 28 2014]
Findings from Shinshu University Hospital Provi... [Published 4 Traders - Aug 28 2014]
Patent Issued for Methods for the Treatment and... [Published 4 Traders - Aug 28 2014]
REGENEUS : AFL approves use of Regeneus Ltd's (... [Published 4 Traders - Aug 27 2014]
StemCutis Attracts Stem Cell Entrepreneur As Pr... [Published BioSpace - Aug 26 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BloodCenter of Wisconsin Launches Erythroid Chi... [Published PR Newswire: Policy & Public Interest - Aug 28 2014]
MILWAUKEE, Aug. 28, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of an innovative Erythroid Chimerism test to monitor erythroid lineage chimerism in patients with sickle cell disease ...
Regeneus in stem cell manufacturing partnership... [Published Proactiveinvestors United Kingdom website - Aug 21 2014]
Regenerative medicine company Regeneus ( ASX:RGS ) has signed an agreement with Cryosite ( ASX:CTE ) to collaborate on the development and manufacture of new stem cell products for human applications.This includes fast-tracking production of its off-the ...
Researchers Identify Tests to Diagnose Invasive... [Published theCSRfeed - Aug 14 2014]
Early, more accurate detection of this potentially deadly fungus can improve patient outcomes, according to new report in The Journal of Molecular Diagnostics SOURCE: Elsevier DESCRIPTION: Philadelphia, PA, August 14, 2014 /3BL Media/ – The fungal ...
Advanced Biologics publishes additional OsteoAM... [Published PR Newswire: General Business - Aug 13 2014]
CARLSBAD, Calif., Aug. 13, 2014 /PRNewswire/ -- Advanced Biologics announced today the acceptance for publication of a new OsteoAMP study to be published in the Journal of Spine.  In the study titled, Clinical Validation of Allogeneic Morphogenetic Protein: ...
テルモBCTがQuantumシステムによる臨床用細胞生産を評価するための提携を発表 [Published Business Wire Science: Science News - Aug 11 2014]
米コロラド州レイクウッド--(BUSINESS WIRE)--Terumo BCT’s Quantum® Cell Expansion System is under evaluation by Athersys, Inc.,as a manufacturing platform for allogeneic multipotent adult progenitor cell products. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
TiGenix Business and Financial Update for the F... [Published GlobeNewswire: Acquisitions News - Aug 26 2014]
Cesca Therapeutics and Fortis Healthcare Announ... [Published GlobeNewswire: Acquisitions News - Aug 05 2014]
TiGenix announces the clinical development of C... [Published GlobeNewswire: Advertising News - Jun 30 2014]
Immunicum’s abstract with data from a kidney ca... [Published GlobeNewswire: Acquisitions News - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.